The Transatlantic Dialogue (TAD) on Public Administration and Management and the Strategic Partnership Between ASPA and EGPA

Established in 2005, the Transatlantic Dialogues (TADs) is a series of conferences that was initiated to address contemporary issues and challenges in public governance, public administration and public management arising from both sides of the Atlantic. The purpose of the TAD is to conjoin academics and practitioners from both Europe and the US around the joint investigation of key topics for the field, especially through comparative methods and approaches. By probing into a different topic of inquiry every year, the TAD series has enabled to integrate the perspectives and cognitive maps of scholars from both sides of the Atlantic to tackle a wide range of issues and produce countless publications. Since the establishment of the TAD series, over 30 conference co-chairs, over 150 workshop co-chairs and 14 American Society of Public Administration (ASPA) presidents from the American side and 3 EGPA presidents from the European side have enabled and supported the TADs. And, crucially, a total of about 1000 participants (at the time this book goes to press) have contributed to make the successive TAD conferences a success

Le projet politique : situation-sens-stratégie : l'acteur au coeur de l'analyse en science politique

Doctorat - UCL

Conclusion: EGPA, EPPA and the Future of Public Administration in Europe

This chapter outlines the strategy of the European Group for Public Administration (EGPA) and reflects on some of its key strengths, and how these may equip the European community of scholars and practitioners of public administration (PA) to contribute to the development of the field. The chapter reviews the key trait of the EGPA organisational model: the Permanent Study Groups, which are communities of scholars centred on the key areas of the administrative sciences in Europe. It also discusses the partnerships that EGPA has developed with key institutions in Europe and beyond, and highlights the significance of the EGPA policy papers on European governance. Finally, it discusses the strategic, forward-looking project European Perspectives on Public Administration, which aims to reflect on the future of the research and teaching of public administration

From MED to EURO MENA: The Many Paths of an Expanded Dialogue

International audienc

From MED to EURO MENA: The Many Paths of an Expanded Dialogue

International audienc

From MED to EURO MENA: The Many Paths of an Expanded Dialogue

International audienc

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

Summary: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union’s Horizon 2020 research and innovation programme and EFPIA